HLA-DR genetic polymorphisms and hepatitis B virus mutations affect the risk of hepatocellular carcinoma in Han Chinese population

Table 4 Significant associations of HLA-DR genetic polymorphisms with frequencies of HCC-related HBV mutations

SNPs	Genotype C HBV infected subjects			Genotype B HBV infected subjects
SNPs	HCC-associated HBV mutation	AOR^a (95% CI)	P value	HCC-associated HBV mutation	AOR^a (95% CI)	P value
rs3135363
AA		Reference			Reference
AG				T1753A/C	0.33 (0.12–0.96)	0.042
				G1896A	0.20 (0.07–0.59)	0.003
rs9268644
CC		Reference			Reference
CA	T1674C/G	0.40 (0.24–0.68)	0.001	T1753A/C	0.34 (0.12–0.65)	0.033
	A1762T/G1764A	0.51 (0.28–0.92)	0.025
	G1899A	0.43 (0.23–0.82)	0.010
	preS deletion	0.55 (0.31–0.96)	0.036
AA	C1653T	0.39 (0.16–0.95)	0.038
	T1753A/C	0.33 (0.12–0.90)	0.030
rs35445101
AA		Reference			Reference
AG	C1653T	0.33 (0.15–0.75)	0.008
	A1762T/G1764A	0.37 (0.16–0.85)	0.019
GG	C1653T	0.44 (0.21–0.93)	0.033
	G1719T	0.37 (0.18–0.76)	0.007
	G1896A	0.44 (0.21–0.89)	0.023
rs24755213
AA					Reference
AG	C1653T	0.58 (0.38–0.88)	0.010	T1753A/C	0.26 (0.08–0.91)	0.035
	T1674C/G	0.45 (0.29–0.69)	3.23 × 10^− 4
	G1719T	0.65 (0.43–0.97)	0.035
	A1762T/G1764A	0.50 (0.32–0.79)	0.003
	A1846T	0.63 (0.39–0.99)	0.046
	G1899A	0.36 (0.21–0.61)	1.32 × 10^− 4
	preS deletion	0.47 (0.29–0.75)	0.002
GG	T1753A/C	0.33 (0.17–0.67)	0.002
	A1846T	0.35 (0.16–0.75)	0.007
	preS deletion	0.49 (0.25–0.97)	0.040
rs984778
TT
TC	C1653T	0.37 (0.23–0.60)	4.15 × 10^− 5
	T1674C/G	0.34 (0.22–0.54)	4.00 × 10^− 6
	G1719T	0.46 (0.30–0.70)	3.01 × 10^− 4
	T1753A/C	0.54 (0.35–0.85)	0.007
	A1762T/G1764A	0.61 (0.37–0.99)	0.046
	A1846T	0.58 (0.36–0.92)	0.021
	G1896A	0.51 (0.33–0.79)	0.002
	G1899A	0.30 (0.16–0.55)	9.56 × 10^− 5

^a AOR, odds ratio adjusted for age, gender, HBeAg, HBV DNA load, ALT, and AST in the comparison between HCC and HBV-infected subjects without HCC.
CI confidence interval, HBV hepatitis B virus, SNP single nucleotide polymorphism

ISSN: 1743-422X